3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 3
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Sarcoma
1
Conditions
Prostatic Neoplasms
3
Lymphoma
2
The Neoadjuvant Therapy
1
Sarcoma, Ewing
1
Sarcoma
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Castration-resistant Prostate Cancer Patients with Oligometastases
1
Interventions
Cyclophosphamide
10
Etoposide
6
Doxorubicin
6
Cytarabine
6
Prednisone
5
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Methotrexate
4
gamma-Globulins
3
Rituximab
3
Radiotherapy
3
Filgrastim
3
Ciprofloxacin
3
pegaspargase
2
nelarabine
2
etoposide phosphate
2
calaspargase pegol
2
Triptorelin Pamoate
2
Thioguanine
2
Prednisolone
2
Methylprednisolone
2
Mercaptopurine
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Immunoglobulins, Intravenous
2
Dexamethasone
2
Daunorubicin
2
Cyclosporine
2
Calcium Dobesilate
2
Bortezomib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoma
×
Triptorelin Pamoate
×
Clear all
NCT02856048
2019-12-17
PRESOV
Assistance Publique - Hôpitaux de Paris
Phase 2/3
Unknown
11 enrolled
NCT01160315
2015-10-30
Erasme-POF
Erasme University Hospital
Phase 2/3
Completed
118 enrolled